We see a world where every genetic condition is understood, and every patient receives the care their need to live their fullest life. Our approach to genetic testing, along with having one of the world's most diverse rare disease data sets, makes us a catalyst for clear, connected and actionable care. Named one of Fast Company's Most Innovative Companies of 2025, we're leading the way to a future where we end the diagnostic odyssey. It all begins with a single test.
$150M sweet spot round size
$150M
from investors over 1 rounds
GeneDx raised $150M on February 27, 2023